Holen Sie sich die Stockscreener-App
5.65
11.16%
-0.71
Handel nachbörslich:
5.78
0.13
+2.30%
Schlusskurs vom Vortag:
$6.36
Offen:
$6.31
24-Stunden-Volumen:
1.97M
Relative Volume:
1.65
Marktkapitalisierung:
$279.29M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.3828
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
+9.92%
1M Leistung:
+20.47%
6M Leistung:
-52.00%
1J Leistung:
+29.29%
1-Tages-Spanne:
$5.635
$6.36
1-Wochen-Bereich:
$4.71
$6.70
52-Wochen-Spanne:
$4.02
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
5.65 | 279.29M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent BioSolutions (EBS) Q1 2025 Earnings Highlight Turnaroun - GuruFocus
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2025 Earnings Call Transcript - Insider Monkey
Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress - MSN
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Emergent Biosolutions: Q1 Earnings Snapshot - Norwalk Hour
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... - Yahoo Finance
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid Revenue Challenges - GuruFocus
Earnings call transcript: Emergent BioSolutions Q1 2025 sees 656% net income rise - Investing.com Nigeria
Emergent Biosolutions earnings beat by $0.22, revenue fell short of estimates - Investing.com
Emergent Biosolutions Q1 2025 slides: turnaround progress drives profitability By Investing.com - Investing.com India
Emergent BioSolutions Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - Yahoo Finance
Emergent BioSolutions Reports 656% Net Income Surge - TipRanks
Emergent BioSolutions (EBS) Updates 2025 Financial Forecast | EBS Stock News - GuruFocus
Emergent BioSolutions (EBS) Reports Strong Q1 Revenue | EBS Stock News - GuruFocus
Emergent BioSolutions Reports First Quarter 2025 Financial Results - The Manila Times
Earnings Flash (EBS) Emergent Biosolutions Posts Q1 Adjusted EPS $0.71, vs. FactSet Est of $0.44 - marketscreener.com
Emergent BioSolutions reports shareholder vote results By Investing.com - Investing.com Nigeria
Emergent BioSolutions Stockholders Elect Directors at Meeting - TipRanks
Emergent BioSolutions reports shareholder vote results - Investing.com
Emergent BioSolutions Inc expected to post earnings of 44 cents a shareEarnings Preview - TradingView
Naloxone Market Rises with Government Initiatives to Combat Opioid Overdose | Emergent BioSolutions, Hikma, Teva - openPR.com
Emergent signs contract to supply Narcan nasal spray in Ontario - Seeking Alpha
Emergent BioSolutions Gets $65M Deal for Ontario Naloxone Program - MarketWatch
Emergent BioSolutions (EBS) Secures $65M Deal with Ontario for N - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency - GuruFocus
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health - The Manila Times
Emergent BioSolutions Lands Major $65M Deal: Ontario Chooses NARCAN to Fight Opioid Crisis - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
Emergent BioSolutions Inc. to Host Conference Call on Q1 2025 Financial Results - Nasdaq
Save The Date: Emergent BioSolutions Q1 2025 Earnings Conference Call Coming May 7 - Stock Titan
Lobbying Update: $920,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Institutional investors in Emergent BioSolutions Inc. (NYSE:EBS) see US$31m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Emergent BioSolutions launches stock repurchase program - MSN
Mile Marker Continues New Business Success With Growth-Oriented Brands - Yahoo Finance
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS - Business Wire
Emergent BioSolutions sets $50 million stock buyback plan By Investing.com - Investing.com South Africa
Emergent BioSolutions Authorizes $50 Million Stock Buyback Program - MarketScreener
Emergent BioSolutions Announces Repurchase Of Up To $50 Mln Stock, Pre-market Stock Up - Nasdaq
Emergent BioSolutions sets $50 million stock buyback plan - Investing.com
$50M Stock Buyback: Emergent BioSolutions Signals Strong Confidence in Turnaround Plan - Stock Titan
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):